Hif1a Cancer Research Results

Hif1a, HIF1α/HIF1a: Click to Expand ⟱
Source:
Type:
Hypoxia-Inducible-Factor 1A (HIF1A gene, HIF1α, HIF-1α protein product)
-Dominantly expressed under hypoxia(low oxygen levels) in solid tumor cells
-HIF1A induces the expression of vascular endothelial growth factor (VEGF)
-High HIF-1α expression is associated with Poor prognosis
-Low HIF-1α expression is associated with Better prognosis

-Functionally, HIF-1α is reported to regulate glycolysis, whilst HIF-2α regulates genes associated with lipoprotein metabolism.
-Cancer cells produce HIF in response to hypoxia in order to generate more VEGF that promote angiogenesis

Key mediators of aerobic glycolysis regulated by HIF-1α.
-GLUT-1 → regulation of the flux of glucose into cells.
-HK2 → catalysis of the first step of glucose metabolism.
-PKM2 → regulation of rate-limiting step of glycolysis.
-Phosphorylation of PDH complex by PDK → blockage of OXPHOS and promotion of aerobic glycolysis.
-LDH (LDHA): Rapid ATP production, conversion of pyruvate to lactate;

HIF-1α Inhibitors:
-Curcumin: disruption of signaling pathways that stabilize HIF-1α (ie downregulate).
-Resveratrol: downregulate HIF-1α protein accumulation under hypoxic conditions.
-EGCG: modulation of upstream signaling pathways, leading to decreased HIF-1α activity.
-Emodin: reduce HIF-1α expression. (under hypoxia).
-Apigenin: inhibit HIF-1α accumulation.
Scientific Papers found: Click to Expand⟱
3329- SIL,    Silymarin regulates the HIF-1 and iNOS expression in the brain and Gills of the hypoxic-reoxygenated rainbow trout (Oncorhynchus mykis)
- in-vivo, Nor, NA
*NO↓, *MDA↓, *TAC↑, *Hif1a↓, *iNOS↓,
3328- SIL,    Modulatory effect of silymarin on inflammatory mediators in experimentally induced benign prostatic hyperplasia: emphasis on PTEN, HIF-1α, and NF-κB
- in-vivo, BPH, NA
*NF-kB↓, *Hif1a↓, *PTEN↑, *Weight↓, *NO↓, *IL6↓, *IL8↓, *COX2↓, *iNOS↓,
3327- SIL,    Effects of silymarin on HIF‑1α and MDR1 expression in HepG‑2 cells under hypoxia
- in-vitro, Liver, HepG2
MDR1↓, Hif1a↓, P-gp↓,
3325- SIL,    Modulatory effect of silymarin on pulmonary vascular dysfunction through HIF-1α-iNOS following rat lung ischemia-reperfusion injury
- in-vivo, Nor, NA
*Inflam↓, *ROS↓, *Casp3↑, *Casp9↑, *Hif1a↓, *iNOS↓, *SOD↑, *MDA↓,
3301- SIL,    Critical review of therapeutic potential of silymarin in cancer: A bioactive polyphenolic flavonoid
- Review, Var, NA
Inflam↓, TumCCA↑, Apoptosis↓, TumMeta↓, TumCG↓, angioG↓, chemoP↑, radioP↑, p‑ERK↓, p‑p38↓, p‑JNK↓, P53↑, Bcl-2↓, Bcl-xL↓, TGF-β↓, MMP2↓, MMP9↓, E-cadherin↑, Wnt↓, Vim↓, VEGF↓, IL6↓, STAT3↓, *ROS↓, IL1β↓, PGE2↓, CDK1↓, CycB/CCNB1↓, survivin↓, Mcl-1↓, Casp3↑, Casp9↑, cMyc↓, COX2↓, Hif1a↓, CXCR4↓, CSCs↓, EMT↓, N-cadherin↓, PCNA↓, cycD1/CCND1↓, ROS↑, eff↑, eff↑, eff↑, HER2/EBBR2↓,
3290- SIL,    A review of therapeutic potentials of milk thistle (Silybum marianum L.) and its main constituent, silymarin, on cancer, and their related patents
- Analysis, Var, NA
hepatoP↑, chemoP↑, *lipid-P↓, *antiOx↑, tumCV↓, TumCMig↓, Apoptosis↑, ROS↑, GSH↓, Bcl-2↓, survivin↓, cycD1/CCND1↓, NOTCH1↓, BAX↑, NF-kB↓, COX2↓, LOX1↓, iNOS↓, TNF-α↓, IL1↓, Inflam↓, *toxicity↓, CXCR4↓, EGFR↓, ERK↓, MMP↓, Cyt‑c↑, TumCCA↑, RB1↑, P53↑, P21↑, p27↑, cycE/CCNE↓, CDK4↓, p‑pRB↓, Hif1a↓, cMyc↓, IL1β↓, IFN-γ↓, PCNA↓, PSA↓, CYP1A1↓,
3289- SIL,    Silymarin: a promising modulator of apoptosis and survival signaling in cancer
- Review, Var, NA
*BioAv↝, *BioAv↓, Fas↑, FasL↑, FADD↑, pro‑Casp8↑, Apoptosis↑, DR5↑, Bcl-2↑, BAX↑, Casp3↑, PI3K↓, FOXM1↓, p‑mTOR↓, p‑P70S6K↓, Hif1a↓, Akt↑, angioG↓, STAT3↓, NF-kB↓, lipid-P↓, eff↑, CDK1↓, survivin↓, CycB/CCNB1↓, Mcl-1↓, Casp9↑, AP-1↓, BioAv↑,
3288- SIL,    Silymarin in cancer therapy: Mechanisms of action, protective roles in chemotherapy-induced toxicity, and nanoformulations
- Review, Var, NA
Inflam↓, lipid-P↓, TumMeta↓, angioG↓, chemoP↑, EMT↓, HDAC↓, HATs↑, MMPs↓, uPA↓, PI3K↓, Akt↓, VEGF↓, CD31↓, Hif1a↓, VEGFR2↓, Raf↓, MEK↓, ERK↓, BIM↓, BAX↑, Bcl-2↓, Bcl-xL↓, Casp↑, MAPK↓, P53↑, LC3II↑, mTOR↓, YAP/TEAD↓, *BioAv↓, MMP↓, Cyt‑c↑, PCNA↓, cMyc↓, cycD1/CCND1↓, β-catenin/ZEB1↓, survivin↓, APAF1↑, Casp3↑, MDSCs↓, IL10↓, IL2↑, IFN-γ↑, hepatoP↑, cardioP↑, GSH↑, neuroP↑,
3282- SIL,    Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions
- Review, NA, NA
hepatoP↑, AntiCan↑, TumCMig↓, Hif1a↓, selectivity↑, toxicity∅, *antiOx↑, *Inflam↓, TumCCA↑, P21↑, CDK4↓, NF-kB↓, ERK↓, PSA↓, TumCG↓, p27↑, COX2↓, IL1↓, VEGF↓, IGFBP3↑, AR↓, STAT3↓, Telomerase↓, Cyt‑c↑, Casp↑, eff↝, HDAC↓, HATs↑, Zeb1↓, E-cadherin↑, miR-203↑, NHE1↓, MMP2↓, MMP9↓, PGE2↓, Vim↓, Wnt↓, angioG↓, VEGF↓, *TIMP1↓, EMT↓, TGF-β↓, CD44↓, EGFR↓, PDGF↓, *IL8↓, SREBP1↓, MMP↓, ATP↓, uPA↓, PD-L1↓, NOTCH↓, *SIRT1↑, SIRT1↓, CA↓, Ca+2↑, chemoP↑, cardioP↑, Dose↝, Half-Life↝, BioAv↓, BioAv↓, BioAv↓, toxicity↝, Half-Life↓, ROS↓, FAK↓,
964- SIL,    Silibinin inhibits hypoxia-induced HIF-1α-mediated signaling, angiogenesis and lipogenesis in prostate cancer cells: In vitro evidence and in vivo functional imaging and metabolomics
- vitro+vivo, Pca, LNCaP - in-vitro, Pca, 22Rv1
TumCP↓, Hif1a↓, NADPH↓, angioG↓, FASN↓, ACC↓,
1001- SIL,    Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolism
- in-vitro, NA, NA
TumCG↓, Glycolysis↓, OXPHOS↑, LDHA↓, lactateProd↓, i-citrate↑, Hif1a↓, PD-L1↓,
2370- SK,    The role of pyruvate kinase M2 in anticancer therapeutic treatments
- Review, Var, NA
Glycolysis↓, PKM2↓, EGFR↓, PI3K↓, p‑Akt↓, Hif1a↓,
2197- SK,    Shikonin derivatives for cancer prevention and therapy
- Review, Var, NA
ROS↑, Ca+2↑, BAX↑, Bcl-2↓, MMP9↓, NF-kB↓, PKM2↓, Hif1a↓, NRF2↓, P53↑, DNMT1↓, MDR1↓, COX2↓, VEGF↓, EMT↓, MMP7↓, MMP13↓, uPA↓, RIP1↑, RIP3↑, Casp3↑, Casp7↑, Casp9↑, P21↓, DFF45↓, TRAIL↑, PTEN↑, mTOR↓, AR↓, FAK↓, Src↓, Myc↓, RadioS↑,
2195- SK,    Shikonin induces ferroptosis in osteosarcomas through the mitochondrial ROS-regulated HIF-1α/HO-1 axis
- in-vitro, OS, NA
TumCP↓, Ferroptosis↓, Hif1a↑, HO-1↑, Iron↑, ROS↑, GSH/GSSG↓, GPx4↓,
2194- SK,    Efficacy of Shikonin against Esophageal Cancer Cells and its possible mechanisms in vitro and in vivo
- in-vitro, ESCC, Eca109 - in-vitro, ESCC, EC9706 - in-vivo, NA, NA
tumCV↓, TumCCA↑, Apoptosis↑, EGFR↓, PI3K↓, Hif1a↓, PKM2↓, cycD1/CCND1↓, AntiTum↑,
2193- SK,    Shikonin Suppresses Lymphangiogenesis via NF-κB/HIF-1α Axis Inhibition
- in-vitro, Nor, HMVEC-dLy
*NF-kB↓, *Hif1a↓, other↓,
3051- SK,    Resveratrol mediates its anti-cancer effects by Nrf2 signaling pathway activation
- Review, Var, NA
Nrf1↑, Apoptosis↑, TumCP↓, eff⇅, chemoP↑, eff↑, VCAM-1↓, Hif1a↓,
3041- SK,    Promising Nanomedicines of Shikonin for Cancer Therapy
- Review, Var, NA
Glycolysis↓, TAMS↝, BioAv↓, Half-Life↝, P21↑, ERK↓, ROS↑, GSH↓, MMP↓, TrxR↓, MMP13↓, MMP2↓, MMP9↓, SIRT2↑, Hif1a↓, PKM2↓, TumCP↓, TumMeta↓, TumCI↓,
965- SK,    Shikonin suppresses proliferation and induces cell cycle arrest through the inhibition of hypoxia-inducible factor-1α signaling
- in-vitro, CRC, HCT116 - in-vitro, CRC, SW-620
Hif1a↓, ROS↓, mTOR↓, p70S6↓, 4E-BP1↓, eIF2α↓, TumCCA↑, TumCP↓, Half-Life↝,
1192- SM,    Abietane diterpenes from Salvia miltiorrhiza inhibit the activation of hypoxia-inducible factor-1
- in-vitro, GC, AGS - in-vitro, Liver, HepG3
Hif1a↓, VEGF↓,
1688- SSE,    Potential Role of Selenium in the Treatment of Cancer and Viral Infections
- Review, Var, NA
IL2↑, INF-γ↑, Th1 response↑, Th2↑, Dose↑, AntiCan∅, Risk↑, chemoP↑, Hif1a↓, VEGF↓, selectivity↑, *GADD45A↑, NRF2↓, *NRF2↑, ChemoSen↑, angioG↓, PrxI↓, ChemoSideEff↓, eff↑,
5331- TFdiG,    Anti-Cancer Properties of Theaflavins
- Review, Var, NA
AntiCan↑, TumCP↓, TumCMig↓, Apoptosis↑, cl‑PARP↑, cl‑Casp3↑, cl‑Casp7↑, cl‑Casp8↑, cl‑Casp9↑, BAX↑, Bcl-2↓, p‑Akt↓, p‑mTOR↓, PI3K↓, cMyc↓, P53↑, ROS↑, NF-kB↓, MMP9↓, MMP2↓, TumVol↓, PSA↓, TumCCA↑, VEGF↓, Hif1a↓, CDK2↓, CDK4↓, GSH↓, Dose↑, BioAv↓, BioAv↓, BioAv↑,
962- TQ,    Thymoquinone affects hypoxia-inducible factor-1α expression in pancreatic cancer cells via HSP90 and PI3K/AKT/mTOR pathways
- in-vitro, PC, PANC1 - in-vitro, Nor, hTERT-HPNE - in-vitro, PC, AsPC-1 - in-vitro, PC, Bxpc-3
TumCMig↓, TumCI↓, Apoptosis↑, Hif1a↓, PI3k/Akt/mTOR↓, TumCCA↑, *toxicity↓, *TumCI∅, *TumCMig∅,
2125- TQ,    Thymoquinone Selectively Kills Hypoxic Renal Cancer Cells by Suppressing HIF-1α-Mediated Glycolysis
- in-vitro, RCC, RCC4 - in-vitro, RCC, Caki-1
Hif1a↓, eff↝, uPAR↓, VEGF↓, CAIX↓, PDK1↓, GLUT1↓, LDHA↓, Glycolysis↓, e-lactateProd↓, i-ATP↓,
2138- TQ,    Thymoquinone has a synergistic effect with PHD inhibitors to ameliorate ischemic brain damage in mice
- in-vivo, Nor, NA
*Hif1a↑, *VEGF↑, *TrkB↑, *PI3K↑, *angioG↑, *neuroG↑, *motorD↑,
2139- TQ,    Thymoquinone regulates microglial M1/M2 polarization after cerebral ischemia-reperfusion injury via the TLR4 signaling pathway
- in-vivo, Nor, NA
*TLR4↓, *NF-kB↓, *Inflam↓, *Hif1a↑, *motorD↑,
3431- TQ,    PI3K-AKT Pathway Modulation by Thymoquinone Limits Tumor Growth and Glycolytic Metabolism in Colorectal Cancer
- in-vitro, CRC, HCT116 - in-vitro, CRC, SW48
Glycolysis↓, Warburg↓, HK2↓, ATP↓, NADPH↓, PI3K↓, Akt↓, TumCP↓, E-cadherin↑, N-cadherin↓, Hif1a↓, PKM2↓, GlucoseCon↓, lactateProd↓, EMT↓,
5022- UA,    Ursolic Acid’s Alluring Journey: One Triterpenoid vs. Cancer Hallmarks
- Review, Var, NA
TumCP↓, Apoptosis↑, angioG↑, TumMeta↓, BioAv↓, Hif1a↓, Glycolysis↓, mitResp↓, Akt↓, MAPK↓, ERK↓, mTOR↓, P53↑, P21↑, E2Fs↑, STAT3↓, MMP↓, NLRP3↓, iNOS↓, CHK1↓, Chk2↓, BRCA1↓, E-cadherin↑, N-cadherin↓, Casp↑, p62↓, LC3II↑, Vim↓, ROS↑, CSCs↓, DNAdam↑, GutMicro↑, VEGF↓,
1067- VitC,    Vitamin C activates pyruvate dehydrogenase (PDH) targeting the mitochondrial tricarboxylic acid (TCA) cycle in hypoxic KRAS mutant colon cancer
- in-vivo, CRC, NA
PDK1↓, Hif1a↓, GLUT1↓, ATP↓, MMP↓,
596- VitC,    High-Dose Vitamin C in Advanced-Stage Cancer Patients
- Review, NA, NA
ChemoSideEff↓, ROS↑, H2O2↑, Fenton↑, Hif1a↝, Dose↑, BioAv↓, Dose↝, Half-Life↝, IL1β↓, IL2↓, IL8↓, TNF-α↓,
632- VitC,    High-Dose Vitamin C: Preclinical Evidence for Tailoring Treatment in Cancer Patients
- Review, NA, NA
SVCT-2∅, ROS↑, Hif1a↓, PARP∅, TET2↑,
3146- VitC,    Vitamin C protects against hypoxia, inflammation, and ER stress in primary human preadipocytes and adipocytes
- in-vivo, Nor, NA
*Obesity↓, *ER Stress↓, *Inflam↓, Hif1a↓, VEGF↓, GLUT1↓, GRP78/BiP↓,
3107- VitC,    Repurposing Vitamin C for Cancer Treatment: Focus on Targeting the Tumor Microenvironment
- Review, Var, NA
Risk↓, *ROS↓, ROS↑, VEGF↓, COX2↓, ER Stress↑, IRE1↑, JNK↑, CHOP↑, Hif1a↓, eff↑, Glycolysis↓, MMPs↓, TumMeta↓, YAP/TEAD↓, eff↑, TET1↑,
3114- VitC,    Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression
- in-vitro, AML, NA
TET2↑, eff↑, ROS↑, Fenton↑, Hif1a↓,
3115- VitC,    The NF-κB Transcriptional Network Is a High-Dose Vitamin C-Targetable Vulnerability in Breast Cancer
- in-vitro, BC, NA
NF-kB↓, Hif1a↓, P53↑,
1219- VitC,    Ascorbic acid and ascorbate-2-phosphate decrease HIF activity and malignant properties of human melanoma cells
- in-vitro, Melanoma, NA
Hif1a↓,
2283- VitK2,    Vitamin K Contribution to DNA Damage—Advantage or Disadvantage? A Human Health Response
- Review, Var, NA
*ER Stress↓, *toxicity↓, *toxicity↑, ROS↑, PI3K↑, Akt↑, Hif1a↑, GlucoseCon↑, lactateProd↑, ChemoSen↑, eff↑, eff↑,
2281- VitK2,    The biological responses of vitamin K2: A comprehensive review
- Review, Var, NA
*ROS↓, *12LOX↓, *NF-kB↓, *BMD↑, *hepatoP↑, cycD1/CCND1↓, PKCδ↓, STAT3↓, ERK↑, MAPK↓, ROS↑, PI3K↝, Akt↝, Hif1a↝, *neuroP↑,
1214- VitK2,    Vitamin K2 promotes PI3K/AKT/HIF-1α-mediated glycolysis that leads to AMPK-dependent autophagic cell death in bladder cancer cells
- in-vitro, Bladder, T24/HTB-9 - in-vitro, Bladder, J82
Glycolysis↑, GlucoseCon↑, lactateProd↑, TCA↓, PI3K↑, Akt↑, AMPK↑, mTORC1↓, TumAuto↑, GLUT1↑, HK2↑, LDHA↑, ACC↓, PDH↓, eff↓, cMyc↓, Hif1a↑, p‑Akt↑, eff↓, eff↓, eff↓, eff↓, ROS↑,
1211- VitK2,    Mechanisms of PKC-Mediated Enhancement of HIF-1α Activity and its Inhibition by Vitamin K2 in Hepatocellular Carcinoma Cells
- in-vitro, HCC, HUH7
Hif1a↓, PKCδ↓,
2301- Wog,    Flavonoids Targeting HIF-1: Implications on Cancer Metabolism
- Review, Var, NA
HK2↓, PDK1↓, LDHA↓, Hif1a↓, PI3K↓, Akt↓, Glycolysis↓, P53↑, GLUT1↓,
2621- Wog,    Natural compounds targeting glycolysis as promising therapeutics for gastric cancer: A review
- Review, Var, NA
Hif1a↓, MCT4↓, LDH↓, lactateProd↓, ECAR↓, TumCP↓, Glycolysis↓,
961- Z,    Zinc Downregulates HIF-1α and Inhibits Its Activity in Tumor Cells In Vitro and In Vivo
- in-vitro, RCC, RCC4 - vitro+vivo, GBM, U373MG - in-vitro, Nor, HUVECs
Hif1a↓, HIF-1↓, VEGF↓, TumCI↓,

Showing Research Papers: 251 to 293 of 293
Prev Page 6 of 6

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 293

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

CYP1A1↓, 1,   Fenton↑, 2,   Ferroptosis↓, 1,   GPx4↓, 1,   GSH↓, 3,   GSH↑, 1,   GSH/GSSG↓, 1,   H2O2↑, 1,   HO-1↑, 1,   Iron↑, 1,   lipid-P↓, 2,   Nrf1↑, 1,   NRF2↓, 2,   OXPHOS↑, 1,   PrxI↓, 1,   ROS↓, 2,   ROS↑, 14,   TrxR↓, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 3,   i-ATP↓, 1,   MEK↓, 1,   mitResp↓, 1,   MMP↓, 6,   Raf↓, 1,  

Core Metabolism/Glycolysis ⓘ

ACC↓, 2,   AMPK↑, 1,   CAIX↓, 1,   i-citrate↑, 1,   cMyc↓, 5,   ECAR↓, 1,   FASN↓, 1,   GlucoseCon↓, 1,   GlucoseCon↑, 2,   Glycolysis↓, 9,   Glycolysis↑, 1,   HK2↓, 2,   HK2↑, 1,   lactateProd↓, 3,   lactateProd↑, 2,   e-lactateProd↓, 1,   LDH↓, 1,   LDHA↓, 3,   LDHA↑, 1,   MCT4↓, 1,   NADPH↓, 2,   PDH↓, 1,   PDK1↓, 3,   PI3k/Akt/mTOR↓, 1,   PKM2↓, 5,   SIRT1↓, 1,   SIRT2↑, 1,   SREBP1↓, 1,   TCA↓, 1,   Warburg↓, 1,  

Cell Death ⓘ

Akt↓, 4,   Akt↑, 3,   Akt↝, 1,   p‑Akt↓, 2,   p‑Akt↑, 1,   APAF1↑, 1,   Apoptosis↓, 1,   Apoptosis↑, 7,   BAX↑, 5,   Bcl-2↓, 5,   Bcl-2↑, 1,   Bcl-xL↓, 2,   BIM↓, 1,   Casp↑, 3,   Casp3↑, 4,   cl‑Casp3↑, 1,   Casp7↑, 1,   cl‑Casp7↑, 1,   cl‑Casp8↑, 1,   pro‑Casp8↑, 1,   Casp9↑, 3,   cl‑Casp9↑, 1,   Chk2↓, 1,   Cyt‑c↑, 3,   DR5↑, 1,   FADD↑, 1,   Fas↑, 1,   FasL↑, 1,   Ferroptosis↓, 1,   iNOS↓, 2,   JNK↑, 1,   p‑JNK↓, 1,   MAPK↓, 3,   Mcl-1↓, 2,   Myc↓, 1,   p27↑, 2,   p‑p38↓, 1,   RIP1↑, 1,   survivin↓, 4,   Telomerase↓, 1,   TRAIL↑, 1,   YAP/TEAD↓, 2,  

Kinase & Signal Transduction ⓘ

HER2/EBBR2↓, 1,   p70S6↓, 1,  

Transcription & Epigenetics ⓘ

HATs↑, 2,   other↓, 1,   p‑pRB↓, 1,   tumCV↓, 2,  

Protein Folding & ER Stress ⓘ

CHOP↑, 1,   eIF2α↓, 1,   ER Stress↑, 1,   GRP78/BiP↓, 1,   IRE1↑, 1,  

Autophagy & Lysosomes ⓘ

LC3II↑, 2,   p62↓, 1,   TumAuto↑, 1,  

DNA Damage & Repair ⓘ

BRCA1↓, 1,   CHK1↓, 1,   DFF45↓, 1,   DNAdam↑, 1,   DNMT1↓, 1,   P53↑, 8,   PARP∅, 1,   cl‑PARP↑, 1,   PCNA↓, 3,  

Cell Cycle & Senescence ⓘ

CDK1↓, 2,   CDK2↓, 1,   CDK4↓, 3,   CycB/CCNB1↓, 2,   cycD1/CCND1↓, 5,   cycE/CCNE↓, 1,   E2Fs↑, 1,   P21↓, 1,   P21↑, 4,   RB1↑, 1,   TumCCA↑, 7,  

Proliferation, Differentiation & Cell State ⓘ

4E-BP1↓, 1,   CD44↓, 1,   CSCs↓, 2,   EMT↓, 5,   ERK↓, 5,   ERK↑, 1,   p‑ERK↓, 1,   FOXM1↓, 1,   HDAC↓, 2,   IGFBP3↑, 1,   mTOR↓, 4,   p‑mTOR↓, 2,   mTORC1↓, 1,   NOTCH↓, 1,   NOTCH1↓, 1,   p‑P70S6K↓, 1,   PI3K↓, 7,   PI3K↑, 2,   PI3K↝, 1,   PTEN↑, 1,   Src↓, 1,   STAT3↓, 5,   TumCG↓, 3,   Wnt↓, 2,  

Migration ⓘ

AP-1↓, 1,   CA↓, 1,   Ca+2↑, 2,   CD31↓, 1,   E-cadherin↑, 4,   FAK↓, 2,   miR-203↑, 1,   MMP13↓, 2,   MMP2↓, 4,   MMP7↓, 1,   MMP9↓, 5,   MMPs↓, 2,   N-cadherin↓, 3,   PDGF↓, 1,   PKCδ↓, 2,   RIP3↑, 1,   TET1↑, 1,   TGF-β↓, 2,   TumCI↓, 3,   TumCMig↓, 4,   TumCP↓, 9,   TumMeta↓, 5,   uPA↓, 3,   uPAR↓, 1,   VCAM-1↓, 1,   Vim↓, 3,   Zeb1↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 6,   angioG↑, 1,   EGFR↓, 4,   HIF-1↓, 1,   Hif1a↓, 32,   Hif1a↑, 3,   Hif1a↝, 2,   LOX1↓, 1,   TAMS↝, 1,   VEGF↓, 13,   VEGFR2↓, 1,  

Barriers & Transport ⓘ

GLUT1↓, 4,   GLUT1↑, 1,   NHE1↓, 1,   P-gp↓, 1,   SVCT-2∅, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 5,   CXCR4↓, 2,   IFN-γ↓, 1,   IFN-γ↑, 1,   IL1↓, 2,   IL10↓, 1,   IL1β↓, 3,   IL2↓, 1,   IL2↑, 2,   IL6↓, 1,   IL8↓, 1,   INF-γ↑, 1,   Inflam↓, 3,   MDSCs↓, 1,   NF-kB↓, 6,   PD-L1↓, 2,   PGE2↓, 2,   PSA↓, 3,   Th1 response↑, 1,   Th2↑, 1,   TNF-α↓, 2,  

Protein Aggregation ⓘ

NLRP3↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 2,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 8,   BioAv↑, 2,   ChemoSen↑, 2,   Dose↑, 3,   Dose↝, 2,   eff↓, 5,   eff↑, 11,   eff⇅, 1,   eff↝, 2,   Half-Life↓, 1,   Half-Life↝, 4,   MDR1↓, 2,   RadioS↑, 1,   selectivity↑, 2,   TET2↑, 2,  

Clinical Biomarkers ⓘ

AR↓, 2,   BRCA1↓, 1,   EGFR↓, 4,   FOXM1↓, 1,   GutMicro↑, 1,   HER2/EBBR2↓, 1,   IL6↓, 1,   LDH↓, 1,   Myc↓, 1,   PD-L1↓, 2,   PSA↓, 3,  

Functional Outcomes ⓘ

AntiCan↑, 2,   AntiCan∅, 1,   AntiTum↑, 1,   cardioP↑, 2,   chemoP↑, 6,   ChemoSideEff↓, 2,   hepatoP↑, 3,   neuroP↑, 1,   radioP↑, 1,   Risk↓, 1,   Risk↑, 1,   toxicity↝, 1,   toxicity∅, 1,   TumVol↓, 1,  
Total Targets: 261

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 2,   lipid-P↓, 1,   MDA↓, 2,   NRF2↑, 1,   ROS↓, 4,   SOD↑, 1,   TAC↑, 1,  

Core Metabolism/Glycolysis ⓘ

12LOX↓, 1,   SIRT1↑, 1,  

Cell Death ⓘ

Casp3↑, 1,   Casp9↑, 1,   iNOS↓, 3,  

Protein Folding & ER Stress ⓘ

ER Stress↓, 2,  

DNA Damage & Repair ⓘ

GADD45A↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

neuroG↑, 1,   PI3K↑, 1,   PTEN↑, 1,  

Migration ⓘ

TIMP1↓, 1,   TumCI∅, 1,   TumCMig∅, 1,  

Angiogenesis & Vasculature ⓘ

angioG↑, 1,   Hif1a↓, 4,   Hif1a↑, 2,   NO↓, 2,   VEGF↑, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   IL6↓, 1,   IL8↓, 2,   Inflam↓, 4,   NF-kB↓, 4,   TLR4↓, 1,  

Synaptic & Neurotransmission ⓘ

TrkB↑, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,   BioAv↝, 1,  

Clinical Biomarkers ⓘ

BMD↑, 1,   IL6↓, 1,  

Functional Outcomes ⓘ

hepatoP↑, 1,   motorD↑, 2,   neuroP↑, 1,   Obesity↓, 1,   toxicity↓, 3,   toxicity↑, 1,   Weight↓, 1,  
Total Targets: 43

Scientific Paper Hit Count for: Hif1a, HIF1α/HIF1a
14 Apigenin (mainly Parsley)
14 Baicalein
14 Resveratrol
14 Sulforaphane (mainly Broccoli)
12 Silymarin (Milk Thistle) silibinin
10 EGCG (Epigallocatechin Gallate)
9 Vitamin C (Ascorbic Acid)
9 Berberine
9 Metformin
8 Shikonin
7 Honokiol
6 Thymoquinone
6 Alpha-Lipoic-Acid
6 Quercetin
5 Artemisinin
5 Betulinic acid
5 Chrysin
5 Curcumin
5 Magnetic Fields
5 Propolis -bee glue
5 Phenethyl isothiocyanate
4 Silver-NanoParticles
4 Ashwagandha(Withaferin A)
4 Radiotherapy/Radiation
4 Chlorogenic acid
4 Dichloroacetate
4 Ellagic acid
4 Graviola
4 Rosmarinic acid
4 Vitamin K2
3 Brucea javanica
3 brusatol
3 borneol
3 Boron
3 Capsaicin
3 Cinnamon
3 Citric Acid
3 Deguelin
3 Magnolol
2 5-fluorouracil
2 Allicin (mainly Garlic)
2 Caffeic acid
2 Carvacrol
2 Celastrol
2 Emodin
2 Electrical Pulses
2 Hydrogen Gas
2 HydroxyTyrosol
2 Luteolin
2 Lycopene
2 Melatonin
2 Oxygen, Hyperbaric
2 Proanthocyanidins
2 Piperlongumine
2 Sanguinarine
2 Wogonin
1 Coenzyme Q10
1 Auranofin
1 alpha Linolenic acid
1 Andrographis
1 Atorvastatin
1 tamoxifen
1 Baicalin
1 Biochanin A
1 Thymol-Thymus vulgaris
1 Sorafenib (brand name Nexavar)
1 Cannabidiol
1 Celecoxib
1 Bortezomib
1 Docosahexaenoic Acid
1 diet FMD Fasting Mimicking Diet
1 Fucoidan
1 Ferulic acid
1 Fenbendazole
1 Fisetin
1 Ai-Tong-An-Gao-Ji
1 Cisplatin
1 flavonoids
1 Gallic acid
1 Gambogic Acid
1 Garcinol
1 Genistein (soy isoflavone)
1 γ-linolenic acid (Borage Oil)
1 HydroxyCitric Acid
1 Ivermectin
1 Juglone
1 Lactobacillus
1 mebendazole
1 metronomic chemo
1 Methylsulfonylmethane
1 Niclosamide (Niclocide)
1 Oroxylin-A
1 Oleuropein
1 doxorubicin
1 Rutin
1 salinomycin
1 Gemcitabine (Gemzar)
1 Salvia miltiorrhiza
1 Selenite (Sodium)
1 Aflavin-3,3′-digallate
1 Ursolic acid
1 Zinc
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:143  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page